Article3 Biotech2025

Potentials of cepharanthine and tomatidine as novel LpxC and TLR4 inhibitors to mitigate gut-mediated inflammation in Parkinson's disease: a high-throughput investigation through molecular docking and dynamic simulation.

Rubina Roy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.